These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 30783971)

  • 21. Delivery of CRISPR/Cas9 system by AAV as vectors for gene therapy.
    Wang Y; Jiang H; Li M; Xu Z; Xu H; Chen Y; Chen K; Zheng W; Lin W; Liu Z; Lin Z; Zhang M
    Gene; 2024 Nov; 927():148733. PubMed ID: 38945310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing.
    Edraki A; Mir A; Ibraheim R; Gainetdinov I; Yoon Y; Song CQ; Cao Y; Gallant J; Xue W; Rivera-Pérez JA; Sontheimer EJ
    Mol Cell; 2019 Feb; 73(4):714-726.e4. PubMed ID: 30581144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineering the Delivery System for CRISPR-Based Genome Editing.
    Glass Z; Lee M; Li Y; Xu Q
    Trends Biotechnol; 2018 Feb; 36(2):173-185. PubMed ID: 29305085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice.
    Nance ME; Shi R; Hakim CH; Wasala NB; Yue Y; Pan X; Zhang T; Robinson CA; Duan SX; Yao G; Yang NN; Chen SJ; Wagner KR; Gersbach CA; Duan D
    Mol Ther; 2019 Sep; 27(9):1568-1585. PubMed ID: 31327755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10.
    Ruan GX; Barry E; Yu D; Lukason M; Cheng SH; Scaria A
    Mol Ther; 2017 Feb; 25(2):331-341. PubMed ID: 28109959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Divergent susceptibilities to AAV-SaCas9-gRNA vector-mediated genome-editing in a single-cell-derived cell population.
    Morsy SG; Tonne JM; Zhu Y; Lu B; Budzik K; Krempski JW; Ali SA; El-Feky MA; Ikeda Y
    BMC Res Notes; 2017 Dec; 10(1):720. PubMed ID: 29221488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The application and progression of CRISPR/Cas9 technology in ophthalmological diseases.
    Hu X; Zhang B; Li X; Li M; Wang Y; Dan H; Zhou J; Wei Y; Ge K; Li P; Song Z
    Eye (Lond); 2023 Mar; 37(4):607-617. PubMed ID: 35915232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CRISPR-Cas9 Genome Editing in Human Cell Lines with Donor Vector Made by Gibson Assembly.
    Sahoo N; Cuello V; Udawant S; Litif C; Mustard JA; Keniry M
    Methods Mol Biol; 2020; 2115():365-383. PubMed ID: 32006411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Applications of CRISPR/Cas9 in retinal degenerative diseases.
    Peng YQ; Tang LS; Yoshida S; Zhou YD
    Int J Ophthalmol; 2017; 10(4):646-651. PubMed ID: 28503441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient viral delivery of Cas9 into human safe harbor.
    Hayashi H; Kubo Y; Izumida M; Matsuyama T
    Sci Rep; 2020 Dec; 10(1):21474. PubMed ID: 33293588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toward In Vivo Gene Therapy Using CRISPR.
    Skipper KA; Mikkelsen JG
    Methods Mol Biol; 2019; 1961():293-306. PubMed ID: 30912053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology.
    Bai B; Myklebust JH; Wälchli S
    Methods Mol Biol; 2020; 2115():445-454. PubMed ID: 32006416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High levels of AAV vector integration into CRISPR-induced DNA breaks.
    Hanlon KS; Kleinstiver BP; Garcia SP; Zaborowski MP; Volak A; Spirig SE; Muller A; Sousa AA; Tsai SQ; Bengtsson NE; Lööv C; Ingelsson M; Chamberlain JS; Corey DP; Aryee MJ; Joung JK; Breakefield XO; Maguire CA; György B
    Nat Commun; 2019 Sep; 10(1):4439. PubMed ID: 31570731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.
    Ohmori T; Nagao Y; Mizukami H; Sakata A; Muramatsu SI; Ozawa K; Tominaga SI; Hanazono Y; Nishimura S; Nureki O; Sakata Y
    Sci Rep; 2017 Jun; 7(1):4159. PubMed ID: 28646206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.
    Wang D; Zhang F; Gao G
    Cell; 2020 Apr; 181(1):136-150. PubMed ID: 32243786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multifunctional AAV-CRISPR-Cas9 and its host response.
    Chew WL; Tabebordbar M; Cheng JK; Mali P; Wu EY; Ng AH; Zhu K; Wagers AJ; Church GM
    Nat Methods; 2016 Oct; 13(10):868-74. PubMed ID: 27595405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New vectors for simple and streamlined CRISPR-Cas9 genome editing in Saccharomyces cerevisiae.
    Laughery MF; Hunter T; Brown A; Hoopes J; Ostbye T; Shumaker T; Wyrick JJ
    Yeast; 2015 Dec; 32(12):711-20. PubMed ID: 26305040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene editing prospects for treating inherited retinal diseases.
    Benati D; Patrizi C; Recchia A
    J Med Genet; 2020 Jul; 57(7):437-444. PubMed ID: 31857428
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Zhou ZP; Yang LL; Cao H; Chen ZR; Zhang Y; Wen XY; Hu J
    Hum Gene Ther; 2019 Sep; 30(9):1101-1116. PubMed ID: 31099266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
    Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
    Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.